Director of the OMRF Multiple Sclerosis Center of Excellence, where MS is approached with optimal clinical care and scientific innovation. Opinions are my own.
Innovative ways to assess disease status and progression in #MS is an unmet need. Proud of our team's work using eye movement analysis as a way to assess cognition and correlate with functional and anatomical metrics @OMRFjournals.sagepub.com/doi/10.…
EBV is required for the development of multiple sclerosis, but it’s not known how a common virus leads to disease. 3 exciting new papers in @CellCellPress provide major insights into how this may occur:
Six-year safety and efficacy outcomes with first-line ofatumumab in re... sciencedirect.com/science/ar…
Exploring longterm effects of early initiation of highly effective treatment as first line in MS; positive data!
Advocacy in action! Fearless Lea Campbell obtained -again- a Governor’s proclamation making March the #NMOSD month in Oklahoma. #MOGAD#raredisease @guthyjacksonfdn @TheSumairaFDN@OMRF
Proud to share ongoing work on novel approaches to quantifying #MS impact. @ViewMind_ Eye movement deficits in Multiple Sclerosis: characterizing executive ... sciencedirect.com/science/ar…
So happy to share the day, knowledge, and experiences with 400 patients and caregivers at Dr. Khatri’s Living Well with #MS and Other Autoimmune Neurological Disorders in Milwaukee. #NMOSD#MOGAD@OMRF
Have you ever wondered about the magnitude of new/unused disease modifying therapies for multiple sclerosis that may be out there? Retail costs for these specialty medicines are near $100K per year!
This is a before and after photo from 2020. Imagine for a minute what we have collected up to present day.
Enthusiasm for fixing the problem is low especially when compensation has already occurred along the distribution chain.
@davidbalat @patientsrising@ectrims@actrims@mssociety@docforms@DrugChannels@elonmusk
⏰ Counting down the days until I present my research at #ECTRIMS2024. Looking forward to engaging discussions and learning from fellow researchers and practitioners.
#MS#msresearchapp.sosha.ai/s/1BG5gydj
Dr. Yang Mao-Draayer will serve as director of clinical and experimental therapeutics in OMRF’s Arthritis and Clinical Immunology Research Program. She also will treat MS patients and direct OMRF’s neuroimmunology lab.
Read more: omrf.org/2024/05/30/omrf-wel…